ccl9 nab Search Results


ccl9 nab  (R&D Systems)
93
R&D Systems ccl9 nab
Figure 4. The effects of <t>CCL9</t> neutralizing antibody administered intrathecally (i.t.) according to timeline (A), at doses of 0.5, 2, and 4 µg/5 µL on mechanical (B) and thermal (C) hypersensitivity, and the influence of a CCL9 neutralizing antibody at a dose of 2 µg/5 µL plus morphine 2.5 µg/5 µL on mechanical (E) and thermal (F) hypersensitivity, administered according to timeline (D), 7 days CCI in mice. The data are presented as the mean ± SEM (naive n = 5; CCI n = 5–8). The results were evaluated using one-way ANOVA followed by Bonferroni’s post hoc test for comparisons of selected pairs. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V-treated group at each of the investigated time points: 1, 4, and 24 h for (B,C) graphs; * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V + W-treated group for (E,F) graphs; # p < 0.05 indicates significant differences between the V + M- and nAb + M-treated groups for (E,F) graphs; and & p < 0.05 indicates significant differences between the nAb + W- and nAb + M-treated groups. Abbreviations: V: vehicle (PBS); W: vehicle (aqua pro injectione); nAb: neutralizing antibody; M: morphine; CCI: chronic constriction injury of the sciatic nerve.
Ccl9 Nab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ccl9 nab/product/R&D Systems
Average 93 stars, based on 1 article reviews
ccl9 nab - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier

Image Search Results


Figure 4. The effects of CCL9 neutralizing antibody administered intrathecally (i.t.) according to timeline (A), at doses of 0.5, 2, and 4 µg/5 µL on mechanical (B) and thermal (C) hypersensitivity, and the influence of a CCL9 neutralizing antibody at a dose of 2 µg/5 µL plus morphine 2.5 µg/5 µL on mechanical (E) and thermal (F) hypersensitivity, administered according to timeline (D), 7 days CCI in mice. The data are presented as the mean ± SEM (naive n = 5; CCI n = 5–8). The results were evaluated using one-way ANOVA followed by Bonferroni’s post hoc test for comparisons of selected pairs. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V-treated group at each of the investigated time points: 1, 4, and 24 h for (B,C) graphs; * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V + W-treated group for (E,F) graphs; # p < 0.05 indicates significant differences between the V + M- and nAb + M-treated groups for (E,F) graphs; and & p < 0.05 indicates significant differences between the nAb + W- and nAb + M-treated groups. Abbreviations: V: vehicle (PBS); W: vehicle (aqua pro injectione); nAb: neutralizing antibody; M: morphine; CCI: chronic constriction injury of the sciatic nerve.

Journal: Brain sciences

Article Title: Pharmacological Modulation of the MIP-1 Family and Their Receptors Reduces Neuropathic Pain Symptoms and Influences Morphine Analgesia: Evidence from a Mouse Model.

doi: 10.3390/brainsci13040579

Figure Lengend Snippet: Figure 4. The effects of CCL9 neutralizing antibody administered intrathecally (i.t.) according to timeline (A), at doses of 0.5, 2, and 4 µg/5 µL on mechanical (B) and thermal (C) hypersensitivity, and the influence of a CCL9 neutralizing antibody at a dose of 2 µg/5 µL plus morphine 2.5 µg/5 µL on mechanical (E) and thermal (F) hypersensitivity, administered according to timeline (D), 7 days CCI in mice. The data are presented as the mean ± SEM (naive n = 5; CCI n = 5–8). The results were evaluated using one-way ANOVA followed by Bonferroni’s post hoc test for comparisons of selected pairs. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V-treated group at each of the investigated time points: 1, 4, and 24 h for (B,C) graphs; * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate significant differences vs. V + W-treated group for (E,F) graphs; # p < 0.05 indicates significant differences between the V + M- and nAb + M-treated groups for (E,F) graphs; and & p < 0.05 indicates significant differences between the nAb + W- and nAb + M-treated groups. Abbreviations: V: vehicle (PBS); W: vehicle (aqua pro injectione); nAb: neutralizing antibody; M: morphine; CCI: chronic constriction injury of the sciatic nerve.

Article Snippet: Administration of CCL3 and CCL9 Neutralizing Antibodies A single i.t. administration of CCL3 nAb (AF-450-NA, Mouse CCL3/MIP-1 alpha Antibody, R&D Systems; Minneapolis, MI, USA) or CCL9 nAb (AF463, Mouse CCL9/10/MIP-1 gamma Antibody, R&D Systems) was administered to CCI mice at the dose of 0.5, 2, or 4 μg/5 μL on Day 7, when mechanical and thermal hypersensitivity were fully developed.

Techniques:

Scheme 1. Pharmacological modulation of chemokines from MIP-1 family (CCL3 and CCL9) via neutralizing antibodies and their receptors (CCR1 by J113863, CCR5 by TAK-220 or AZD -5672) reduces neuropathic pain symptoms and influences morphine analgesia—evidence from mice model evoked by chronic constriction injury of the sciatic nerve.

Journal: Brain sciences

Article Title: Pharmacological Modulation of the MIP-1 Family and Their Receptors Reduces Neuropathic Pain Symptoms and Influences Morphine Analgesia: Evidence from a Mouse Model.

doi: 10.3390/brainsci13040579

Figure Lengend Snippet: Scheme 1. Pharmacological modulation of chemokines from MIP-1 family (CCL3 and CCL9) via neutralizing antibodies and their receptors (CCR1 by J113863, CCR5 by TAK-220 or AZD -5672) reduces neuropathic pain symptoms and influences morphine analgesia—evidence from mice model evoked by chronic constriction injury of the sciatic nerve.

Article Snippet: Administration of CCL3 and CCL9 Neutralizing Antibodies A single i.t. administration of CCL3 nAb (AF-450-NA, Mouse CCL3/MIP-1 alpha Antibody, R&D Systems; Minneapolis, MI, USA) or CCL9 nAb (AF463, Mouse CCL9/10/MIP-1 gamma Antibody, R&D Systems) was administered to CCI mice at the dose of 0.5, 2, or 4 μg/5 μL on Day 7, when mechanical and thermal hypersensitivity were fully developed.

Techniques: